Banque Cantonale Vaudoise Makes New Investment in Becton, Dickinson and Company $BDX

Banque Cantonale Vaudoise bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,435 shares of the medical instruments supplier’s stock, valued at approximately $643,000.

A number of other large investors also recently modified their holdings of the stock. SOA Wealth Advisors LLC. raised its position in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Activest Wealth Management boosted its position in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 97 shares during the last quarter. Bell Investment Advisors Inc increased its stake in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares during the period. Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 139 shares during the last quarter. Finally, Accredited Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 70 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $159.37 on Friday. The firm has a market capitalization of $45.38 billion, a P/E ratio of 26.00, a PEG ratio of 11.83 and a beta of 0.24. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The business has a 50-day moving average of $190.72 and a 200-day moving average of $190.28. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same period last year, the company posted $3.43 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.6%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,416 shares of company stock worth $674,693. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of a number of research reports. Piper Sandler reiterated a “neutral” rating and issued a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 target price on the stock. Jefferies Financial Group dropped their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.